CD133 has been suggested as a molecular marker of CSCs in multiple tumor studies including NPC.48, 49, 50, 51, 52 Our results also suggested that CNE‐2R‐CD133+ cells had a strong in vitro proliferation capacity and in vivo tumorigenesis capacity, thus preliminarily verifying that CNE‐2R‐CD133+ cells are CSCs. This evidence concerns the gene PROM1 and neoplasm.